Meda's acquisition of Acton Pharmaceuticals completed
Monday, 21 October 2013
On August 30th, 2013, Meda announced the acquisition of Acton
Pharmaceuticals, Inc. and its proprietary product Aerospan. The company
can now announce that the acquisition has now been completed.
The purchase price for Acton amounted to 135 MUSD, on a cash and debt
free basis. In addition, there is a milestone payment of 10 million USD
and royalty based milestones. About Aerospan Aerospan
Aerospan (flunisolide HFA, 80 mcg) is approved by the U.S. Food and
Drug Administration (“FDA”) for the treatment of asthma in adult and
paediatric patients 6 years of age and older. Aerospan is the first and
only product registered in the US market with a built-in inhalation
chamber (called a “spacer”) which assists in the delivery of the
medicine to the lungs.
Did you spot any error(s) or had any problem with the above article. Please contact us